Cargando…

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors

BACKGROUND: Histone deacetylase inhibitors (HDACi) are promising antineoplastic agents, but their precise mechanisms of actions are not well understood. In particular, the relevance of p53 for HDACi-induced effects has not been fully elucidated. We investigated the anticancer effects of four structu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonnemann, J, Marx, C, Becker, S, Wittig, S, Palani, C D, Krämer, O H, Beck, J F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915118/ https://www.ncbi.nlm.nih.gov/pubmed/24281001 http://dx.doi.org/10.1038/bjc.2013.742

Ejemplares similares

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

p53 mutation, deprivation and poor prognosis in primary breast cancer
por: Baker, L, et al.
Publicado: (2010)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
por: Jonsson, Marte, et al.
Publicado: (2016)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
por: Canner, J A, et al.
Publicado: (2009)

New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
por: Sorriento, D, et al.
Publicado: (2015)

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
por: Arts, J, et al.
Publicado: (2007)

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
por: Tao, Y, et al.
Publicado: (2007)

Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells
por: Hennig, D, et al.
Publicado: (2015)

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
por: Wu, Chiao-En, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation
por: Lopergolo, A, et al.
Publicado: (2009)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
por: Ali, A, et al.
Publicado: (2013)

Combination therapy with PEG-IFN-α and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53
por: Hagiwara, S, et al.
Publicado: (2007)

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
por: Isham, C R, et al.
Publicado: (2012)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
por: Mrakovcic, Maria, et al.
Publicado: (2017)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2
por: Fedier, A, et al.
Publicado: (2002)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines
por: Liem, A A, et al.
Publicado: (2003)

Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation
por: Hostanska, K, et al.
Publicado: (2003)

Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells
por: Lucia, M B, et al.
Publicado: (2011)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
por: Diallo, J-S, et al.
Publicado: (2008)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
por: Smith, N F, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_m909sdpe0o5ub9205laphs5lc0